Loading
Life sciences · Journal article
BMC Cancer · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
To develop and validate a hybrid prognostic model integrating clinical, MRI, and radiomics features for predicting overall survival (OS) in patients with colorectal cancer liver metastases (CRCLM) undergoing targeted therapy. This retrospective, multicenter study included 118 CRCLM patients who received targeted therapy at two tertiary hospitals. Patients were divided into training, internal test, and external validation cohorts. Clinical, MRI, and radiomics features were comprehensively collected. Multiple radiomics models—including intratumoral, peritumoral, combined, and delta models—were constructed. The optimal model was selected and combined with key clinical and imaging features to build a hybrid prognostic model. Model performance was evaluated using area under the receiver operating characteristic curve (AUC), calibration, and risk stratification by Kaplan–Meier analysis. Tumor related to adjacent vein (TRTAV), and the radiomics-derived Rad-score were identified as independent predictors of OS. The hybrid model demonstrated superior prognostic accuracy compared to single-feature models, with robust AUCs for 1-, 2-, and 3-year OS prediction across all cohorts. Risk stratification by the hybrid model revealed significant survival differences between low- and high-risk groups (all p < 0.05). The proposed hybrid model, integrating MRI and radiomics features, enables accurate, non-invasive prediction of OS in CRCLM patients undergoing targeted therapy and outperforms RECIST 1.1 in survival stratification, supporting individualized prognosis and clinical decision-making. This study received the approval of the two Institutional Review Boards ( No.LLHBCH2025YN-082 for Hubei Cancer Hospital; No.UHCT-IEC-SOP-016–03-01 for Wuhan Union Hospital).